370 related articles for article (PubMed ID: 30528147)
1. [Treatment with oral anticoagulants in older patients: Should warfarin still be prescribed?].
Lafuente-Lafuente C; Oasi C; Belmin J
Presse Med; 2019 Feb; 48(2):154-164. PubMed ID: 30528147
[TBL] [Abstract][Full Text] [Related]
2. [Anticoagulation of older patients: what is new?].
Lafuente-Lafuente C; Pautas É; Belmin J
Presse Med; 2013 Feb; 42(2):187-96. PubMed ID: 23312927
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
5. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
6. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
8. Overview of the new oral anticoagulants: opportunities and challenges.
Yeh CH; Hogg K; Weitz JI
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
[TBL] [Abstract][Full Text] [Related]
9. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Zirlik A; Bode C
J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
Kozlowski D; Budrejko S; Raczak G; Rysz J; Banach M
Curr Pharm Des; 2013; 19(21):3816-26. PubMed ID: 23286429
[TBL] [Abstract][Full Text] [Related]
12. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
13. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
14. The new oral anticoagulants: Reasonable alternatives to warfarin.
Roca B; Roca M
Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.
Ment J
Vasc Health Risk Manag; 2015; 11():317-32. PubMed ID: 26089678
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA
Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
[No Abstract] [Full Text] [Related]
17. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Dzeshka MS; Lip GY
Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran for the prevention and treatment of thromboembolic disorders.
Enriquez A; Baranchuk A; Redfearn D; Simpson C; Abdollah H; Michael K
Expert Rev Cardiovasc Ther; 2015 May; 13(5):529-40. PubMed ID: 25843430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
